These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 657108

  • 41. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ.
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract] [Full Text] [Related]

  • 42. Clinical and molecular insights into BCG immunotherapy for melanoma.
    Kremenovic M, Schenk M, Lee DJ.
    J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
    [Abstract] [Full Text] [Related]

  • 43. Multiple cutaneous malignant melanomas with features of primary melanoma.
    Unger SW, Wanebo HJ, Cooper PH.
    Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
    [Abstract] [Full Text] [Related]

  • 44. Immunology and cutaneous malignant melanoma.
    Sober AJ.
    Int J Dermatol; 1976 Feb; 15(1):1-18. PubMed ID: 1107238
    [No Abstract] [Full Text] [Related]

  • 45. Recall skin-test antigens and the prognosis of stage I melanoma.
    Aranha GV, McKhann CF, Simmons RL, Grage TB.
    J Surg Oncol; 1979 Feb; 11(1):13-6. PubMed ID: 431077
    [Abstract] [Full Text] [Related]

  • 46. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
    Helander I, Nordman E, Häkkinen IP, Toivanen A.
    Br J Dermatol; 1979 Oct; 101(4):421-7. PubMed ID: 508607
    [Abstract] [Full Text] [Related]

  • 47. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P.
    Dermatology; 1996 Oct; 193(2):105-9. PubMed ID: 8884144
    [Abstract] [Full Text] [Related]

  • 48. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.
    Bulkley GB, Cohen MH, Banks PM, Char DH, Ketcham AS.
    Cancer; 1975 Aug; 36(2):485-94. PubMed ID: 1157014
    [Abstract] [Full Text] [Related]

  • 49. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
    Balzarini GP, Cascinelli N, Fontana V, Veronesi U.
    Tumori; 1974 Aug; 60(4):345-52. PubMed ID: 4439501
    [No Abstract] [Full Text] [Related]

  • 50. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM, Wells HB, Case LD, Spurr CL, White DR, Richards F, Muss HB, Jackson DV, Stuart JJ, Cooper MR.
    Cancer; 1985 Feb 15; 55(4):707-12. PubMed ID: 3967167
    [Abstract] [Full Text] [Related]

  • 51. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC, Cosimi AB, Carey RW, Kaufman SD.
    Surgery; 1978 Jun 15; 83(6):677-81. PubMed ID: 644461
    [Abstract] [Full Text] [Related]

  • 52. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK, Ho VC.
    J Dermatol Surg Oncol; 1993 Nov 15; 19(11):985-90. PubMed ID: 8245304
    [Abstract] [Full Text] [Related]

  • 53. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.
    Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, Fair WR, Oettgen HF.
    J Clin Oncol; 1987 Mar 15; 5(3):441-9. PubMed ID: 3546618
    [Abstract] [Full Text] [Related]

  • 54. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL, Jessup JM, Cohen MH.
    Arch Surg; 1978 Jul 15; 113(7):893-6. PubMed ID: 678104
    [Abstract] [Full Text] [Related]

  • 55. [Activity of 2,4 dinitrochlorbenzene skin tests during the course of immunotherapy of malignant melanomas].
    Richter J, Duchková H, Kubíková M.
    Cas Lek Cesk; 1975 Sep 26; 114(39):1201-3. PubMed ID: 1182748
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS.
    Cancer; 1983 Jan 01; 51(1):57-60. PubMed ID: 6821809
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.